1.21
3.97%
-0.05
시간 외 거래:
1.21
전일 마감가:
$1.26
열려 있는:
$1.15
하루 거래량:
113.09K
Relative Volume:
2.65
시가총액:
$20.39M
수익:
-
순이익/손실:
$-52.53M
주가수익비율:
-0.3048
EPS:
-3.97
순현금흐름:
$-39.93M
1주 성능:
-13.57%
1개월 성능:
-17.12%
6개월 성능:
-24.84%
1년 성능:
-41.26%
Unity Biotechnology Inc Stock (UBX) Company Profile
명칭
Unity Biotechnology Inc
전화
(650) 416-1192
주소
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-01-04 | 업그레이드 | ROTH Capital | Neutral → Buy |
2021-11-10 | 업그레이드 | Mizuho | Neutral → Buy |
2021-06-28 | 업그레이드 | Citigroup | Sell → Buy |
2021-06-07 | 개시 | H.C. Wainwright | Buy |
2021-02-16 | 다운그레이드 | Citigroup | Neutral → Sell |
2020-08-18 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-08-18 | 다운그레이드 | Mizuho | Buy → Neutral |
2020-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-08-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2020-07-28 | 개시 | ROTH Capital | Buy |
2019-12-12 | 개시 | Cantor Fitzgerald | Overweight |
2019-03-07 | 개시 | Cantor Fitzgerald | Overweight |
2018-09-07 | 개시 | Mizuho | Buy |
2018-05-29 | 개시 | Citigroup | Buy |
2018-05-29 | 개시 | Goldman | Neutral |
2018-05-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Unity Biotechnology Inc 주식(UBX)의 최신 뉴스
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St
Unity Biotechnology Focuses on Promising DME Treatment - TipRanks
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Empery Asset Management, LP Acquires Shares in Volcon Inc - Yahoo Finance UK
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
Empery Asset Management's Strategic Reduction in Sharps Technology Inc - Yahoo Finance
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire
Unity Biotechnology (FRA:9U90) Cash Ratio : 3.85 (As of Jun. 2024) - GuruFocus.com
Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - Defense World
Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World
Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Meiji Yasuda Asset Management Co Ltd. Buys 33 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic
Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Uniti Group Inc [UNIT] stock was sold by Mudry Ronald J. at the price of US$0.11 million - Knox Daily
1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World
Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia
Meeder Advisory Services Inc. Invests $36,000 in Uniti Group Inc. (NASDAQ:UNIT) - Defense World
Unity Software Inc. (NYSE:U) Shares Bought by Daiwa Securities Group Inc. - Defense World
Commonwealth Equity Services LLC Has $1.16 Million Position in Unity Software Inc. (NYSE:U) - Defense World
Court rules against United Therapeutics in Liquidia case - Investing.com India
Royal London Asset Management Ltd. Boosts Stake in Unity Software Inc. (NYSE:U) - Defense World
694 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Caprock Group LLC - Defense World
Anti-Senescence Therapy Market is Likely to Upsurge at USD 25.16 Bn- Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa – Daily News Mirror - Daily News Mirror
The Top 8 Things to Know About Anti-Aging Research Right Now - upworthyscience.com
UBX (Unity Biotechnology) Debt-to-Equity : 1.10 (As of Jun. 2024) - GuruFocus.com
Billionaires are spending big so they — and maybe you — can live forever - MarketWatch
Unity Biotechnology (FRA:9U90) Net-Net Working Capital : €0.01 (As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
UBX (Unity Biotechnology) EPS (Basic) : $-1.74 (TTM As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) Growth Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
UBX (Unity Biotechnology) Short-Term Debt & Capital Lease O - GuruFocus.com
UBX (Unity Biotechnology) Purchase Of Investment : $-28.03 Mil (TTM As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) Intrinsic Value: Projected FCF : $-30.17 (As of Aug. 17, 2024) - GuruFocus.com
Unity Biotechnology (FRA:9U90) Cash From Discontinued Inves - GuruFocus.com
UBX (Unity Biotechnology) GF Value : $0.00 (As of Aug. 16, 2024) - GuruFocus.com
UNITY Biotechnology to Participate in Upcoming Investor Conferences - GlobeNewswire
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Unity Biotechnology, Inc. Expected to Post Q3 2024 Earnings of ($0.40) Per Share (NASDAQ:UBX) - Defense World
Unity Biotechnology (NASDAQ:UBX) Posts Earnings Results - Defense World
FY2028 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Boosted by Analyst - Defense World
Unity Biotechnology Inc (UBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):